Johnson & Johnson s one-dose vaccine closes in on U S approval metro.us - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from metro.us Daily Mail and Mail on Sunday newspapers.
BioNTech, Moderna shore up supplies of key COVID-19 vaccine ingredients
FILE PHOTO: A nurse fills a syringe with a second dose of the Pfizer-BioNTech COVID-19 vaccine, as the coronavirus disease (COVID-19) outbreak continues, at Enfermera Isabel Zendal new pandemic hospital in Madrid, Spain, February 4, 2021. REUTERS/Sergio Perez/File Photo reuters tickers
This content was published on February 12, 2021 - 13:29
February 12, 2021 - 13:29
By Allison Martell, Ludwig Burger and Chad Terhune
(Reuters) - Vaccine makers are shoring up their supply of a critical raw material in messenger RNA vaccines: the lipid molecules that help deliver the genetic RNA material into cells.
Manufacturers are under pressure to increase production of COVID-19 vaccines as infections from the pandemic approach 110 million people.
Vaccine makers are shoring up their supply of a critical raw material in "messenger RNA" vaccines: the lipid molecules that help deliver the genetic RNA material into cells.
Polina Ivanova, Rinat Sagdiev, Anton Zverev
4 分钟阅读 Many participants had already quit to seek vaccination Current volunteers will not be “unblinded” Other vaccine makers facing same ethical challenge
By Polina Ivanova, Rinat Sagdiev and Anton Zverev
MOSCOW, Dec 22 (Reuters) - Russia stopped taking in new volunteers in the trial of its first vaccine against COVID-19 on Wednesday, with developers saying it was unethical to administer a placebo to participants now that the shot was increasingly available to the public.
Russia began rolling out the Sputnik V vaccine as part of a national inoculation programme in early December as the final, phase III trial continued in the capital at the same time.